Literature DB >> 23951516

Osteoarthritis, a disease bridging development and regeneration.

Rik J U Lories1, Frank P Luyten.   

Abstract

The osteoarthritic diseases are common disorders characterized by progressive destruction of the articular cartilage in the joints, and associated with remodeling of the subchondral bone, synovitis and the formation of bone outgrowths at the joint margins, osteophytes. From the clinical perspective, osteoarthritis leads to joint pain and loss of function. Osteoarthritis is the leading cause of progressive disability. New data from genetic, translational and basic research have demonstrated that pathways with essential roles in joint and bone development also contribute to the postnatal homeostasis of the articular cartilage and are involved in osteoarthritis, making these potential therapeutic targets. Other systems of interest are the tissue-destructive enzymes that break down the extracellular matrix of the cartilage as well as mediators of inflammation that contribute to synovitis. However, the perspective of a durable treatment over years to decades highlights the need for a personalized medicine approach encompassing a global view on the disease and its management, thereby including nonpharmaceutical approaches such as physiotherapy and advanced surgical methods. Integration of novel strategies based on their efficacy and safety with the identification of individuals at risk and optimal individual rehabilitation management remains a major challenge for the medical community in particular, as the incidence of osteoarthritis is likely to further increase with the overall aging of the population.

Entities:  

Year:  2012        PMID: 23951516      PMCID: PMC3727791          DOI: 10.1038/bonekey.2012.136

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  55 in total

1.  Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms.

Authors:  Carla R Scanzello; Brian McKeon; Bryan H Swaim; Edward DiCarlo; Eva U Asomugha; Veero Kanda; Anjali Nair; David M Lee; John C Richmond; Jeffrey N Katz; Mary K Crow; Steven R Goldring
Journal:  Arthritis Rheum       Date:  2011-02

2.  Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis.

Authors:  Ana M Valdes; Tim D Spector; Agu Tamm; Kalle Kisand; Sally A Doherty; Elaine M Dennison; Massimo Mangino; Ann Tamm; Irina Kerna; Deborah J Hart; Margaret Wheeler; Cyrus Cooper; Rik J Lories; Nigel K Arden; Michael Doherty
Journal:  Arthritis Rheum       Date:  2010-08

Review 3.  A review of the ADAMTS family, pharmaceutical targets of the future.

Authors:  Micky D Tortorella; Fransiska Malfait; Ruteja A Barve; Huey-Sheng Shieh; Anne-Marie Malfait
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  Changing the outcome of osteoarthritis: still a challenge for cyclooxygenase 2 inhibitors.

Authors:  Rik J U Lories
Journal:  Arthritis Rheum       Date:  2012-01

5.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

6.  Mutations in CDMP1 cause autosomal dominant brachydactyly type C.

Authors:  A Polinkovsky; N H Robin; J T Thomas; M Irons; A Lynn; F R Goodman; W Reardon; S G Kant; H G Brunner; I van der Burgt; D Chitayat; J McGaughran; D Donnai; F P Luyten; M L Warman
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1.

Authors:  J T Thomas; M W Kilpatrick; K Lin; L Erlacher; P Lembessis; T Costa; P Tsipouras; F P Luyten
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

8.  Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes.

Authors:  Marjan M C Steenvoorden; Tom W J Huizinga; Nicole Verzijl; Ruud A Bank; H Karel Ronday; Hilco A F Luning; Floris P J G Lafeber; René E M Toes; Jeroen DeGroot
Journal:  Arthritis Rheum       Date:  2006-01

Review 9.  A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis.

Authors:  Peter M van der Kraan; Esmeralda N Blaney Davidson; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2010-01-29       Impact factor: 5.156

10.  Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification.

Authors:  Gust Verbruggen; Ruth Wittoek; Bert Vander Cruyssen; Dirk Elewaut
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103

View more
  2 in total

Review 1.  Joint problems arising from lack of repair mechanisms: can cannabinoids help?

Authors:  Natalia Malek; Katarzyna Starowicz
Journal:  Br J Pharmacol       Date:  2018-04-22       Impact factor: 8.739

2.  Phlpp1 facilitates post-traumatic osteoarthritis and is induced by inflammation and promoter demethylation in human osteoarthritis.

Authors:  E W Bradley; L R Carpio; M E McGee-Lawrence; C Castillejo Becerra; D F Amanatullah; L E Ta; M Otero; M B Goldring; S Kakar; J J Westendorf
Journal:  Osteoarthritis Cartilage       Date:  2015-12-31       Impact factor: 6.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.